TG Therapeutics Inc
Открыт
СекторЗдравоохранение
50 1.09
Обзор
Изменение цены акций
24 ч
Мин.
47.82
Макс.
49.87
Доход | -3.3M 20M |
|---|---|
Продажи | 12M 205M |
P/E Средняя по отрасли | 14.318 49.052 |
Прибыль на акцию | 0.18 |
Рентабельность продаж | 9.651 |
Сотрудники | 399 |
EBITDA | -17M 35M |
Рекомендации | Покупка |
|---|---|
Прогноз на 12 месяцев | -5.9% downside |
Следующий отчет о доходах | 3 авг. 2026 г. |
|---|
Рыночная капитализация | 803M 6.3B |
|---|---|
Предыдущая цена открытия | 48.91 |
Предыдущая цена закрытия | 50 |
Новостные настроения
By Acuity
20%
80%
36 / 342 Рейтинг в Healthcare
TG Therapeutics Inc График
Прошлые результаты не являются надежным индикатором будущих результатов.
О компании TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.